

# Accepted Manuscript

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

Jatin J. Shah, MD, Rafat Abonour, MD, Christina Gasparetto, MD, James W. Hardin, PhD, Kathleen Toomey, MD, Mohit Narang, MD, Shankar Srinivasan, PhD, Amani Kitali, MPH, Faiza Zafar, MPAS, E. Dawn Flick, PhD, Robert M. Rifkin, MD

PII: S2152-2650(17)30692-4

DOI: [10.1016/j.clml.2017.06.013](https://doi.org/10.1016/j.clml.2017.06.013)

Reference: CLML 947


To appear in: *Clinical Lymphoma, Myeloma and Leukemia*

Received Date: 9 May 2017

Accepted Date: 8 June 2017

Please cite this article as: Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, Srinivasan S, Kitali A, Zafar F, Flick ED, Rifkin RM, Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes, *Clinical Lymphoma, Myeloma and Leukemia* (2017), doi: 10.1016/j.clml.2017.06.013.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Shah CONNECT MM Baseline Demographics (May 1, 2017)

**Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes**

Jatin J. Shah, MD;<sup>a</sup> Rafat Abonour, MD;<sup>b</sup> Christina Gasparetto, MD;<sup>c</sup> James W. Hardin, PhD;<sup>d</sup> Kathleen Toomey, MD;<sup>e</sup> Mohit Narang, MD;<sup>f</sup> Shankar Srinivasan, PhD;<sup>g</sup> Amani Kitali, MPH;<sup>g</sup> Faiza Zafar, MPAS;<sup>g</sup> E. Dawn Flick, PhD;<sup>g</sup> Robert M. Rifkin MD<sup>h</sup>

**Author Affiliations:** <sup>a</sup> M.D. Anderson Cancer Center, Houston, TX; <sup>b</sup> Indiana University Simon Cancer Center, Indianapolis, IN; <sup>c</sup> Duke University Medical Center, Durham, NC; <sup>d</sup> University of South Carolina, Columbia, SC; <sup>e</sup> Steeplechase Cancer Center, Somerville, NJ; <sup>f</sup> US Oncology Research, Maryland Hematology Oncology, Columbia, MD; <sup>g</sup> Celgene Corporation, Summit, NJ; <sup>h</sup> US Oncology Research, The Woodlands, TX, and Rocky Mountain Cancer Centers, Denver, CO.

**Corresponding Author:** Jatin J. Shah, MD

Email: jatinshahmd@gmail.com

**Word count:** 3581

Download English Version:

<https://daneshyari.com/en/article/5581722>

Download Persian Version:

<https://daneshyari.com/article/5581722>

[Daneshyari.com](https://daneshyari.com)